Co-Pay and Reimbursement
Katerzia is Affordable and Accessible
Backed by robust coverage and reimbursement support
- Covered by commercial managed care plans.
- Reimbursed by Medicaid in every state.
- Dedicated Prior Authorization Hotline: 1-844-472-2032.
- Co‐pay support and/or patient assistance available for qualifying patients.
Katerzia Patients with Commercial Insurance Pay No More Than $30 for a Katerzia Prescription
Backed by robust coverage and reimbursement support
- Real-time savings at over 70,000 pharmacies with the Katerzia co-pay programs.
- Automatic savings—Applies electronic coupon to co-pay.
- Completely paperless—No physician cards or coupons needed.
- This program is for patients covered by commercial insurance.
Some of the participating pharmacies include:
- Costco Pharmacy
- CVS Pharmacy
- Duane Reade
- Genuardi’s Pharmacy
- Giant Pharmacy
- Harris Teeter
- Kroger Pharmacy
- Rite Aid Pharmacy
- Sam’s Pharmacy
- Target Pharmacy
- Walmart Pharmacy
For patients without commercial insurance, there are other options for gaining access to Katerzia:
- Katerzia is covered by Medicaid.
- A patient assistance program is available for those who qualify.
* Eligibility Restrictions, Terms and Conditions
By participating in this savings program, participants understand and agree that the information provided, as well as non-personally identifiable information obtained from the pharmacy, will be shared with the manufacturer and with any companies working with the manufacturer. Participants also affirm that they will not submit, and have not had submitted on their behalf, a claim for reimbursement or coverage for items purchased with this card under Medicaid, Medicare, TRICARE, or any other federal or state government healthcare program, or where prohibited by state law.
- Offer applies to out‐of‐pocket expenses (co‐pay) greater than $30. Out‐of‐pocket expenses greater than $30 will be covered up to $230 per prescription. If your total out‐of‐pocket cost exceeds $230, you will be responsible for a $30 co‐pay plus any additional amount over $230. If your co‐pay is already $30 or less, this offer does not apply.
- Offer applies only to Katerzia Oral Suspension patients and associated refills.
- This offer is not valid for prescriptions paid in part or in full by any federally or state‐funded program, including but not limited to Medicaid, Medicare, Department of Veterans Affairs, Department of Defense, or TRICARE, and where prohibited by law.
- For questions about eVoucherRx™, please call: 800‐388‐2316 Relay Pharmacy Help Desk/Customer Support.
- For questions about Voucher On Demand™, please call: 866‐379‐6389 eRx Network, LLC Help Desk/Customer Support.
- This savings program cannot be combined with any other coupon, certificate, voucher, or similar offer.
- Offer good only in the USA at participating retail pharmacies and cannot be redeemed at government‐subsidized clinics. Void where taxed, restricted, or prohibited by law.
- Offer not extended to clubs, groups, or organizations.
- Participation in this program must comply with all applicable laws and contractual or other obligations as a pharmacy provider.
- This is not an insurance program.
- Participating patients and pharmacists understand and agree to comply with the Terms and Conditions of this offer as set forth herein.
- Any step‐edits or prior authorizations required by the insurance plan still apply.
- Azurity Pharmaceuticals, Inc. reserves the right to modify or cancel this program at any time.
- eVoucherRx™ and Voucher On Demand™ are not extended on prescriptions for patients:
- who are cash‐paying customers.
- using institution-based pharmacies to fill their prescriptions, or who are recipients of federal or state government health care.
- who are filling their prescriptions at nonparticipating pharmacies.
eVoucherRx™ is a trademark of RelayHealth.
Voucher On Demand™ is a trademark of eRx Network, LLC.
IMPORTANT SAFETY INFORMATION
KATERZIA® (amlodipine) Oral Suspension, 1 mg/mL
KATERZIA is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of:
- Hypertension in adults and children 6 years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
- Coronary Artery Disease:
- Chronic stable angina.
- Vasospastic angina (Prinzmetal’s or Variant Angina).
- Angiographically documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40%.
ADDITIONAL IMPORTANT SAFETY INFORMATION:
KATERZIA is contraindicated in patients with known sensitivity to amlodipine.
Warnings and Precautions:
Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. Because of the gradual onset of action, acute hypotension is unlikely.
Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of KATERZIA, particularly in patients with severe obstructive coronary artery disease.
Because KATERZIA is extensively metabolized by the liver, and the plasma elimination half-life is 56 hours in patients with impaired hepatic function, titrate slowly when administering KATERZIA to patients with severe hepatic impairment.
Adverse Reactions: See Full Prescribing Information for additional Adverse Reactions (6).
The most common dose-related adverse reaction to amlodipine is edema.
Incidents of dose-related dizziness, flushing, and palpitation also have been observed.
For several reported adverse experiences that appear to be drug and dose related (edema, flushing, palpitations), there was a greater incidence in women than in men associated with amlodipine treatment.
Other adverse experiences not dose-related but reported are fatigue, nausea, abdominal pain, and somnolence.
Impact of Other Drugs on Amlodipine
Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction.
Monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A inhibitors to determine the need for dose adjustment.
Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers.
Impact of Amlodipine on Other Drugs:
Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.
Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended and adjust the dose when appropriate.
Use in Specific Populations: See Full Prescribing Information for Additional Information (8).
Limited data on post-marketing use of amlodipine in pregnant women are not sufficient to inform a drug-associated risk for major birth defects or miscarriages. There are risks to the mother and fetus associated with poorly controlled hypertension during pregnancy.
Limited available data from a published clinical lactation study reports that amlodipine is present in human milk. No adverse effects of amlodipine on the breastfed infant have been observed.
Amlodipine (2.5 to 5 mg daily) is effective in lowering blood pressure in patients 6 to 17 years. The effect of amlodipine on blood pressure in patients less than 6 years of age is not known.
In general, dose selection for elderly patients should be cautious, usually starting with a lower initial dose.
A lower initial dose may be required for patients with hepatic insufficiency.
This Important Safety Information does not include all the information needed to use KATERZIA safely and effectively. Visit KATERZIA.com for Full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals at 1-855-379-0383, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.